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Abstract: Histone deacetylation, together with altered acetylation of NF-κB/RelA, encompassing the
K310 residue acetylation, occur during brain ischemia. By restoring the normal acetylation condition,
we previously reported that sub-threshold doses of resveratrol and entinostat (MS-275), respectively,
an activator of the AMP-activated kinase (AMPK)-sirtuin 1 pathway and an inhibitor of class I
histone deacetylases (HDACs), synergistically elicited neuroprotection in a mouse model of ischemic
stroke. To improve the translational power of this approach, we investigated the efficacy of MS-275
replacement with valproate, the antiepileptic drug also reported to be a class I HDAC blocker.
In cortical neurons previously exposed to oxygen glucose deprivation (OGD), valproate elicited
neuroprotection at 100 nmol/mL concentration when used alone and at 1 nmol/mL concentration
when associated with resveratrol (3 nmol/mL). Resveratrol and valproate restored the acetylation of
histone H3 (K9/18), and they reduced the RelA(K310) acetylation and the Bim level in neurons
exposed to OGD. Chromatin immunoprecipitation analysis showed that the synergistic drug
association impaired the RelA binding to the Bim promoter, as well as the promoter-specific H3
(K9/18) acetylation. In mice subjected to 60 min of middle cerebral artery occlusion (MCAO),
the association of resveratrol 680 µg/kg and valproate 200 µg/kg significantly reduced the infarct
volume as well as the neurological deficits. The present study suggests that valproate and resveratrol
may represent a promising ready-to-use strategy to treat post-ischemic brain damage.
Keywords: valproate; resveratrol; oxygen glucose deprivation (OGD); middle cerebral artery
occlusion (MCAO); RelA
1. Introduction
Stroke is one of the leading causes of mortality and morbidity worldwide with an increasing
number of reports and clinical trials performed every year. The only approved pharmacological
treatment for ischemic stroke is tissue plasminogen activator (tPA) within 4.5 h from the ischemic
event [1]. However, due to the increased risk of hemorrhagic conversion in the infarcted brain,
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tPA administration after 4.5 h of the stroke onset is contraindicated and generally results in
negative outcomes. To date, the identification of a neuroprotective therapy remains an unmet
need [2]. Stroke pathogenesis is complex and involves numerous processes including excitotoxicity,
oxidative damage, apoptosis and inflammation [3–6].
In the last few years different studies demonstrated that epigenetic changes occur during brain
ischemia. In particular, histone deacetylation and the modification of NF-κB/RelA acetylation seem
to be involved in stroke pathophysiology [7–9]. Among post-translational modifications of histones,
acetylation plays an essential role in the gene activation regulating the accessibility of chromatin to
the transcriptional machinery [10]. Acting in an opposite way, histone acetyltransferase (HAT) and
histone deacetylase (HDAC) reversibly regulate the acetylation of lysine residues. A general decrease
of HAT activity lead to the over-deacetylation described in brain ischemia [11,12], so that application
of HDAC inhibitors showed a therapeutic efficacy in mice models of middle cerebral artery occlusion
(MCAO) [13–17]. Recently, it has been demonstrated that suppressing HDAC2 in the peri-infarct cortex
of rodents promotes the motor function recovery at day 8 after stroke, opening a new therapeutic
window for the treatment of stroke [18].
Beside histones, other non-histone proteins that comprise transcription factors such as NF-κB,
are targets of HATs and HDACs [19]. NF-κB acts in the central nervous system as a pleiotropic
regulator of genes controlling either cell survival [20] or the apoptosis and inflammation associated with
neurodegeneration [21,22]. In previous studies we showed that the acetylation state of NF-κB/RelA
(RelA) and histones can discriminate protective and neurotoxic effects elicited by NF-κB in brain
ischemia [8,9,23]. Either the neuroprotective ischemic preconditioning or the noxious ischemia
activated the p50/RelA dimer, but only the ischemic injury induced an atypical RelA acetylation
on Lys 310 residue with a statistically relevant reduction of H3 histone acetylation. In parallel with the
RelA Lys310 acetylation, the interaction of RelA with the histone acetyltransferase cAMP-response
element binding protein CREB-binding protein (CBP)/p300 complex also increased [8]. In primary
cortical neurons exposed to oxygen glucose deprivation (OGD) and in the cortex of mice exposed
to “MCAO”, these changes were associated with RelA detachment from the anti-apoptotic Bcl-xL
promoter and binding to the pro-apoptotic Bim [9] or the 1B-divalent metal transporter (1B-DMT1)
promoter [24].
The acetylation levels of both RelA and histones are regulated by histone deacetylases (HDACs)
and histone acetyl transferases (HATs) [19]. The class I HDAC’s members (HDAC1-3) deacetylate
NF-κB/RelA [25], while the atypical class III HDAC, sirtuin 1, selectively deacetylates the lysine 310
(K310) of RelA [8,26]. With the aim of restoring the altered acetylation of RelA and of histones after
brain ischemia, we previously studied the combined association of entinostat (MS-275), a specific
class I HDAC inhibitor, together with resveratrol, a sirtuin 1 activator [9]. MS-275 is a synthetic
benzamide derivative under clinical evaluation for cancer therapy [27]. MS-275 has been demonstrated
to inhibit HDACs1-3, and it is endowed with excellent pharmacokinetic properties [27]. The resveratrol
mechanism of action includes the activation of the longevity factors SIRT1 [28] and AMP-activated
kinase (AMPK), a serine-threonine kinase known to be a key metabolic and stress sensor/effector [29].
It has been shown that the small-chain-fatty-acid compound valproate inhibits the HDACs [30].
In particular valproate has major inhibitory activity on class I HDACs1,2,3 and 8 (millimolar range),
while has no effects on HDACs 6,7 and 9 [31]. As a class I HDACs inhibitor, valproate could
represent an alternative to MS-275, with the advantage to be suitable to the translational application
in human brain ischemia, being routinely used to treat epileptic and bipolar patients. Notably,
valproate was reported to be neuroprotective per se either in animal and cellular model of brain
ischemia [32–35]. Clinical studies also demonstrated improved outcome in patients affected by
intracerebral hemorrhage [36] or acute middle cerebral artery infarction when treated with the
anti-epileptic doses of valproate [37]. On these premises, here we studied the effect of valproate
in the association with resveratrol, both in the in vitro model of cortical neurons exposed to OGD and
in mice subjected to transient “MCAO”.
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2. Results
2.1. Valproate Elicits Synergistic Neuroprotection with Resveratrol in Mouse Cortical Neurons Exposed to
OGD (Oxygen Glucose Deprivation)
We previously demonstrated that apoptosis preceded necrosis in OGD-exposed primary cultures
of mouse cortical neurons. Within 2 and 6 h after OGD, neuronal cells displayed release of cytochrome
c and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positivity, respectively,
in the absence of lactate dehydrogenase (LDH) release. The progressive release of cellular LDH
became clearly detectable in the culture medium 24 h after the OGD, as an index of secondary
necrosis [35]. In this experimental setting, the association of resveratrol and MS-275 elicited a synergistic
neuroprotection [9]. The therapeutic potential of the drug association was confirmed in a MCAO
model of brain ischemia [9]. By using both the same experimental approaches, we here tested the
neuroprotective activity of resveratrol in association with valproate. Mouse primary cortical neurons,
previously exposed to 3 h of OGD, were treated with valproate in the following 24 h. Valproate was
tested at concentration ranging from 0.01 to 100 nmol/mL, alone or in association with 3 nmol/mL
resveratrol. Valproate was neuroprotective per se at 100 nmol/mL concentration, while in association
with resveratrol it was active at 1 nmol/mL concentration (Figure 1).
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Figure 1. Valproate (VPA) and resveratrol elicited neuroprotective effects in primary cortical neurons
exposed to oxygen glucose deprivation (OGD). VPA (100 nmol/mL), added during the 24 h recovery
period, showed per se a significant neuroprotective activity. The combination of concentrations,
per se ineffective, of resveratrol (3 nmol/mL) and VPA (1 nmol/mL) led to maximal neuroprotection.
Values were expressed as a percentage of neurotoxicity, measured performing an lactate dehydrogenase
(LDH) assay. Bars depicted the mean ± s.e.m. (Standard Error of the Mean) from three separate
experiments run in triplicate. * p < 0.05 versus the corresponding OGD value. For statistical analysis
one way ANOVA followed by Bonferroni post hoc test was performed.
2.2. Association of Valproate and Resveratrol Normalizes the Acetylation State of Histones and RelA
e evaluated hether the neuroprotective effect of the drug co bination as associated ith
the capability of valproate to inhibit neuronal DACs, even at the lo concentration used [30].
estern blot analyses of lysine acetylation at histones H3 and H4 were perfor ed in nuclear extracts
fro cortical neurons exposed to OGD and treated with resveratrol (3 n ol/mL) and/or valproate
(1 nmol/mL) in the following 2 h. In line with the effect observed by co bining resveratrol and
S-275 [9], the co bination of resveratrol and valproate restored the acetylation levels of H3 (K9/18),
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reduced by OGD (Figure 2A). The combined drugs did not increase the acetylation state of H4 (K16)
(Figure 2B). As previously found with resveratrol alone (3 nmol/mL) [9], valproate alone (1 nmol/mL)
did not affect histone acetylation.
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Figure 2. Western blots analyses of the H3 and H4 acetylation levels in nuclear extracts from OGD-
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acetylation. Treatment with combined VPA (1 nmol/mL) and resveratrol (3 nmol/mL) completely 
restored the histone H3 acetylation. In the densitometry analysis of immunoblot bands data were 
expressed as percentage of the corresponding control value. Bars depicted the mean ± s.e.m. of three 
separate experiments, * p < 0.05 and ** p < 0.01 versus the corresponding OGD value. 
Further co-immunoprecipitation (co-IP) analyses of nuclear extracts by specific anti-RelA 
antibodies were performed to investigate the level of RelA activation and acetylation. In line with 
previous evidence [8,9], OGD exposure induced the nuclear translocation of RelA as well as the 
RelA(K310) acetylation. Differently from resveratrol [9] or valproate alone, the combined application 
of the two drugs effectively reduced RelA(K310) acetylation (Figure 3). 
Figure 2. Western blots analyses of the H3 and H4 acetylation levels in nuclear extracts from
OGD-exposed cortical neurons treated for 2 h with valproate (VPA) alone or in combination with
resveratrol. (A,B) VPA (1 nmol/mL) did not increase per se the amount of H3 (K9/18) and H4 (K16)
acetylation. Treatment with combined VPA (1 nmol/mL) and resveratrol (3 nmol/mL) completely
restored the histone H3 acetylation. In the densito etry analysis of i unoblot bands data were
expressed as percentage of the corresponding control value. Bars depicted the ean s.e. . of three
separate experi ents, * p < 0.05 and ** p < 0.01 versus the corresponding value.
Further co-immunoprecipitation (co-IP) analyses of nuclear extracts by specific anti-RelA
antibodies were performed to investigate the level of RelA activation and acetylation. In line with
previous evidence [8,9], OGD exposure induced the nuclear translocation of RelA as well as the
RelA(K310) acetylation. Differently from resveratrol [9] or valproate alone, the combined application
of the two drugs effectively reduced RelA(K310) acetylation (Figure 3).
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Figure 3. Effect of the valproate (VPA) and resveratrol combination on RelA acetylation state in
OGD-exposed primary cortical neurons. Co-immunoprecipitation (co-IP) analysis of RelA acetylation
in nuclear extracts of OGD-exposed cells treated during the following 2 h with vehicle or drugs.
The combination of the drugs (VPA 1 nmol/mL and resveratrol 3 nmol/mL) site-specifically decreased
the RelA K310 acetylation. In the densitometry analysis of immunoblot bands relative to RelA,
data were expressed as percentage of the corresponding control value. Bars depicted the mean ± s.e.m.
of three separate experiments, * p < 0.05 and ** p < 0.01 versus the corresponding OGD value.
2.3. Association of Valproate and Resveratrol Reduces the Activation of the Pro-Apoptotic Bim Promoter in
ortical eurons
It has been reported that during OGD exposure of cortical neurons, the stimulation of
Ac-RelA(K310) transactivates the pro-apoptotic Bim promoter [7–9]. Chro atin i unoprecipitation
( hIP) assays in cellular or ani al odels of brain ische ia also established that activated el binds
the endogenous Bi pro oter [9,23,24].
Like ise resveratrol and S-275 association [9], the addition of resveratrol (3 nmol/ L) and
valproate (1 n ol/ L) to the cells, in the 2 h after the exposure, totally i paired the el
binding at the Bi pro oter as ell as the consequent promoter-specific H3 (K9/18) acetylation
(Figure 4 ,B). These data correlated ith the Bi protein level in the cytoplas . fter 2 h of recovery
fro the , the Bi a ount appeared increased, but it as reduced in cells exposed to resveratrol
and valproate (Figure 4 ).
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H3 acetylatio (K9/18) t, he Bim promoter. Results were btained by real-time polymerase chain
reaction (qRT-PCR) nalyses of Bim promoter in im un precipitated DNA. Data w re expressed
as fold changes over values obtained in cells maintain d in normal oxygen–glucose conditi n.
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the corresponding control value; (C) Treatment with combined VPA (1 nmol/mL) a d resveratrol
(3 nmol/mL) significantly attenu ted the Bim protein increase after OGD exposure. In the densitome ry
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2.4. Valproate Elicits Synergistic Neuroprotection with Resveratrol in Experimental Mouse Model of
Brain Ischemia
In mice subjected to 60 min of MCAO, the drugs were injected i.p. (intraperitoneally) 30 min after
the beginning of the reperfusion period. Resveratrol was tested i her at 680 or 6800 µg/kg. On the
basis of 1:10 valproate-MS-275 relative potency [9] in in vitro neuroprotection (0.1 nmol/mL MS-275
vs. 1 nmol/mL valproate), valproate was t sted in assoc at on with resveratrol at 200 µg/kg, a tenfold
increase over the dose of MS-275 previously used in the synergistic combination with resveratrol [9]
(Figure 5). Valproate was also tested alone at th antiepileptic dose of 20,000 µg/kg.
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Twenty-four hours after ischemia, neurological function was scored in mice according to two
scales: a general neurological scale and a focal neurological scale, as described in the Materials and
Methods section [38,39]. The association of resveratrol 680 µg/kg and valproate 200 µg/kg significantly
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reduced the infarct volume (57.8 ± 1.8 vs. 32.8 ± 5, Figure 5A), as well as the neurological deficits
(Figure 5B,C) when compared to vehicle treated animals. Worthy of note, on the basis of valproate
pharmacokinetics [40], is the fact that the dose of 200 µg/kg i.p. in MCAO mice (Figure 5) was expected
to produce a valproate brain concentration of ~1 nmol/mL, the same concentration that elicited
synergistic neuroprotection with resveratrol in primary neurons exposed to OGD (Figure 1). When used
separately at the same doses, neither the drugs produced neuroprotection (resveratrol 680 µg/kg:
51.6 ± 4.1; valproate 200 µg/kg: 52.2 ± 4.4, Figure 5A). Only when used at the higher doses
(resveratrol 6,8 mg/kg or valproate 20 mg/kg) did they limit the infarct volume (resveratrol: 41.7 ± 3.9;
valproate: 34.4 ± 3.8) and show a distribution of neurological scores slightly lower, although not
statistically significant (Figure 5B,C).
3. Discussion
The present work gives preclinical evidence for the synergistic efficacy of resveratrol when
administered with valproate, the old and largely used antiepileptic drug reported to inhibit the class I
HDACs [30]. We here demonstrate that a valproate concentration of 1 nmol/mL elicited a synergistic
neuroprotection with resveratrol (3 nmol/mL) in primary neurons exposed to OGD. When used alone,
valproate was neuroprotective only at a concentration 100 folds higher (100 nmol/mL) than that
effective in the synergy with resveratrol.
Different studies evidenced the increased histone acetylation as a pivotal epigenetic mechanism
that promotes gene expression [41–43]. In line with previous evidence [9,44,45], we here confirmed the
reduction of both histone H3 and H4 acetylation in cells exposed to OGD. This effect was reasonably
related to a reduced HAT activity generated by the lower availability of acetyl-CoA, the fundamental
co-factor for HAT enzymes, in response to the energy depletion due to the ischemic condition [46,47].
It has been demonstrated that the pharmacological inhibition of HDACs during brain ischemia
increases histone acetylation [13]. This effect on the H3 histone was produced by either MS-275 [23] or
valproate when used in association with resveratrol at very low concentrations. Neither valproate or
MS-275 [9] or resveratrol [9] were able to increase the H3 acetylation when used individually at such
low concentrations. Conversely, in neurons exposed to OGD, a single administration of resveratrol
(3 nmol/mL) was found to be already effective in activating AMPK by promoting its phosphorylation
at Thr 172 [9]. It is conceivable that AMPK, by inducing the catabolic pathways associated with ATP
and NAD+ production contributes to the generation of acetyl-CoA in neuronal cells [48,49] which
in turn can sustain the H3 acetylation in the presence of HDAC inhibitors, a mechanism that can
contribute to the observed synergistic effect.
Valproate was not able to restore the histone H4 acetylation when combined with resveratrol
at our experimental conditions. It could be explained by the short time (2 h) of recovery after OGD
adopted in our investigation. Valproate showed to increase the histone H4 acetylation in rat models
of brain ischemia, but only at later times from the onset of brain ischemia (72 h) and after repeated
administration of the antiepileptic doses (300 µg/kg) [33,45]. An observation that would suggest a
differential involvement of H3 and H4 acetylation in the early phases of neuroprotection.
NAD+, provided by AMPK, is the fundamental co-factor for sirtuins. Thus, AMPK may indirectly
sustain sirtuin 1 activation by resveratrol [49]. As a proof of the involvement of AMPK-sirtuin pathway
in the synergistic effect of resveratrol and HDAC inhibitors, either the compound C-mediated AMPK
inhibition, or sirtuin 1 inhibition by sirtinol were found to abolish the neuroprotection induced by
the combination of MS-275 and resveratrol in OGD-exposed neurons [9]. A recognized target of the
deacetylase activity of sirtuin 1 [8,26] is RelA acetylated at the K310 residue and the association of
resveratrol and valproate effectively reduced the RelA K310 acetylation. Clear-cut demonstration of the
pro-apoptotic transcription mediated by acetylated RelA at the K310 has been previously provided by
replacing lysine at the 310 residue with the acetylation-resistant arginine in mutagenesis experiments
on RelA. Expressing the mutated RelA subunit in neurons abolished the OGD-mediated transcription
of Bim [8] and DMT1 [24] promoter luciferase plasmids and preserved the cell survival. ChIP analysis
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showed that either OGD in cells or lethal ischemia in mice induced the RelA binding and H3 (K9/18)
histone acetylation at the endogenous promoters of DMT-1 and Bim [8,9,24]. As previously reported
for MS-275 and resveratrol [9], valproate and resveratrol totally hampered the binding of RelA, as well
as the following H3 (K9/18) histone acetylation, at the Bim promoter in cultured neurons exposed
to OGD. These effects correlated with a reduced cellular content of Bim protein. It can be inferred
that as a result of 3 h of OGD exposure, the RelA binding at the Bim promoter increased the gene
expression and the Bim protein levels. After the brief recovery (2 h) in the presence of the drugs,
only the early phase of the protein drop to the control levels could be detectable, although its decrease
was already significant.
We also demonstrated that administration of very low doses of valproate (200 µg/kg i.p.)
and resveratrol (680 µg/kg i.p.) in mice subjected to MCAO significantly reduced infarct volume
and neurological deficits. When used individually at the same low doses, neither the drugs
produced neuroprotection. At higher doses they limited the infarct volume and induced a slight,
not significant, reduction of neurological scores. Notably, in the synergistic combination with
resveratrol, valproate reduced the neurological deficits at a dose at least a hundredfold lower than that
commonly used in the seizure treatment [37], an aspect of the synergy that could unveil a much safer
use of valproate for the clinical management of brain injury in post-ischemic patients. On the basis of
pharmacokinetics evidence [40], the neuroprotective dose of valproate (200 µg/kg i.p) is expected to
produce a valproate brain concentration of ~1 nmol/mL, the same concentration that we demonstrated
to be neuroprotective with resveratrol in OGD-exposed primary neurons.
It can be concluded that valproate and resveratrol, by displaying a synergistic neuroprotective
activity, may represent a promising, ready-to-use strategy for the therapy of post-ischemic
brain damage.
Notably, a clinical study examining the use of valproate 400 mg/Bid versus placebo in
post-stroke patients revealed no significant difference on the occurrence of comorbidities or seizure
at one year. Though at one year it revealed a significant benefit in the secondary outcome of the
National Institutes of Health Stroke Scale (NIHSS) score in the valproate-treated patients [36]. Also,
a next open-label trial showed that post insult treatment with valproate (500 mg/Bid for three
months) improved functional recovery in patients with acute middle cerebral artery infarction [37],
suggesting a neuroprotective/neuro-remodeling effect of valproate when given at antiepileptic doses.
Among valproate side effects, the most reported are dose-related and include tremor, gastrointestinal
disturbances, bodyweight gain, liver toxicity, pancreatitis and neurological disorders [40]. By exploiting
the combination with resveratrol, the present study discloses the translational potential to use valproate
in post-stroke patients at much lower doses and drastically reduce the side effects of the drug in
chronic treatments.
4. Material and Methods
4.1. Cell Culture
Primary cultures of mouse cortical neurons derived from 15-day-old embryonic mice, harvested with
caesarean section from anaesthetized pregnant C57Bl/6 dams (Charles River, Italy) and cultured as
previously described [50]. An initial plate density of 1.0 × 104 cells/mm2 was used and 20 mm2
culture dishes were used for the viability studies, 210 mm2 culture dishes for Western blot and
co-immunoprecipitation analyses and 560 mm2 culture dishes (Nunc, Langenselbold, Germany) for
chromatin immunoprecipitation (ChIP) assays. All experiments were carried out at 11 days in vitro (DIV).
4.2. Oxygen Glucose Deprivation and Measurement of Lactate Dehydrogenase (LDH) Release
Primary cortical neurons at the eleventh DIV were exposed to OGD for 3 h, as previously
described [50]. Control cells were incubated in a normal aerated incubator for the same time period.
Cells recovered for 24 h in culture medium (Neurobasal medium containing 0.4% B27 supplement)
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typically aerated in the incubator. At the end of the recovery, neuronal injury was evaluated by
measuring the amount of lactate dehydrogenase (LDH) (Promega, Madison, WI, USA) released
relative to total releasable LDH. Different concentrations of valproate (from 0.1 to 100 nmol/mL)
or resveratrol (3 nmol/mL) alone or combined were added to the cells after the OGD period.
Valproate (Sigma-Aldrich, Saint Louis, MO, USA) was dissolved in recovery medium and resveratrol
(Merck KGaA, Darmstadt, Germany) in dimethyl sulfoxide (DMSO) and diluted to a final DMSO
concentration lower than 0.3%. Control cells were treated with vehicle.
4.3. Co-Immunoprecipitation and Western Blot Analyses
Immunoprecipitation and Western blot studies of RelA and histone acetylation were performed
in nuclear protein extracts prepared as previously described [50] from primary cortical neurons
exposed to 3 h of OGD and maintained 2 h in recovery medium in presence or absence of
valproate (1 nmol/mL) and/or resveratrol (3 nmol/mL). Briefly, a total of 40 µg of nuclear extracts
were incubated at 4 ◦C overnight with 2 µg/µL of goat polyclonal anti-RelA antibody (sc-372GX,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and co-immunoprecipitated proteins were detected
by immunoblotting. The following antibodies were used: rabbit polyclonal anti-RelA (1:100, sc-372,
Santa Cruz Biotechnology), rabbit polyclonal anti-Acetyl-RelA (Lys310) (1:500, #3045, Cell Signaling,
Danvers, MA, USA).
For Western blot analyses, nuclear proteins (15–20 µg proteins/sample) were resolved by
Bolt™ 4–12% Bis-Tris Plus SDS/polyacrylamide pre-cast gels (Invitrogen, Waltham, MA, USA).
Immunodetection was performed by incubating the membrane overnight at 4 ◦C, with the following
primary antibodies: rabbit anti-H3 (#9715 Cell Signaling), rabbit anti-Acetyl H3 (K9-18) (#07-593
Upstate-Millipore, Billerica, MA, USA), rabbit anti-H4 (#07-108 Upstate-Millipore), rabbit anti-Acetyl
H4 (K16) (#06-762 Upstate-Millipore).
For western blot analyses of Bim protein 30 µg of cytosolic extracts were resolved by Bolt™ 10%
Bis-Tris Plus SDS/polyacrylamide pre-cast gels (Invitrogen). Immunodetection was performed by
incubating the membrane overnight at 4 ◦C, with the following primary antibodies: rabbit anti-Bim
(#14-6265 eBioscience, Waltham, MA, USA) and mouse anti-actin (#A4700 Sigma-Aldrich).
Quantification of protein expression was performed by densitometry analysis of immunoblots,
using Gel Pro.3 analysis software (MediaCybernetics, Rockville, MD, USA).
4.4. Chromatin Immunoprecipitation Assay and Real-Time PCR Analysis
Chromatin immunoprecipitation (ChIP) assays were performed in primary cortical neurons as
previously described [9]. The ChIP assay kit (#9003S, Cell Signaling Technology) was used to study H3
histone acetylation and RelA binding at the Bim promoter. Primary cultures of mouse cortical neurons
were exposed to 3 h of OGD and then treated with valproate (1 nmol/mL) and resveratrol (3 nmol/mL)
for 2 h in recovery medium. The sheared chromatin was incubated with anti-acetyl H3 (K9/18) or
anti-RelA or anti-IgG (negative control) overnight at 4 ◦C. An aliquot of chromatin, not incubated
with antibody, was used as the input control sample. Antibody-bound protein/DNA complexes was
washed, eluted, treated with proteinase digest proteins, and subjected to real-time polymerase chain
reaction (qRT-PCR) analyses.
The specific primers used to amplify the mouse Bim promoter were as follows:
forward, 5-CTGGATGCAGGTTGGGTAG-3
reverse, 5-GGGAATGAGAAAGTTAGCTGGA-3
These specific primers generated a 410-bp product. Incorporation of the SYBR Green dye into
the PCR products was monitored in real-time with a ViiA™ 7 Real-Time PCR detection system
(Applied Biosystems, Waltham, MA, USA), allowing the determination of the threshold cycle (Ct) at
which the exponential amplification of PCR products began.
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4.5. Transient Middle-Cerebral Artery Occlusion Model (MCAO)
Mice were subjected to MCAO as previously described [51,52]. A 5-0 nylon filament was inserted
through the external carotid artery stump and advanced into the left internal carotid artery until it
blocked the origin of the middle cerebral artery (MCA). After 60 min MCA occlusion, the filament
was withdrawn to restore blood flow. Body temperature was monitored throughout the entire
duration of the surgical procedure and maintained at 37.5 ◦C with a thermostatic blanket. Experiments
were performed according to the international guidelines for animal research and approved by the
Animal Care Committee of “Federico II” University of Naples, Italy and by Italian Minister of Health
(11 May 2015), Autorization n. 355/2015-PR.
4.6. Monitoring of Blood Gas Concentration and Cerebral Blood Flow (CBF) with Laser-Doppler Flowmetry
A catheter was inserted into the femoral artery to measure arterial blood gases before and
after ischemia (Rapid lab 860; Chiron Diagnostic, Medfield, MA, USA). CBF was monitored in the
cerebral cortex ipsilateral to the occluded MCA with a laser-doppler flowmeter (Periflux system, 5000,
Perimed AB, Järfälla, Sweden) [53]. Once a stable CBF signal was obtained, the MCA was occluded.
CBF monitoring was continued up to 30 min after the end of the surgical procedure once the occurred
reperfusion was verified.
4.7. Evaluation of Ischemic Volume and Neurologic Deficit Scores
Mice were decapitated 24 h after ischemia. Ischemic volume was evaluated by
2,3,5-triphenyltetrazolium chloride staining [54]. The brains were cut into 500 µm coronal
slices with a vibratome (Campden Instrument, 752 M, Loughborough, UK). Sections were incubated
in 2% 2,3,5-triphenyltetrazolium chloride for 20 min and in 10% formalin overnight. The infarcted
area was calculated by image analysis software (Image-Pro Plus, Rockville, MD, USA) [55]. The total
infarct volume was expressed as a percentage of the volume of the hemisphere ipsilateral to the lesion.
In mice, 24 h after ischemia, neurological function was scored according to two scales: a general
neurological scale and a focal neurological scale, as described by Clark et al. (1997) [38]. In the general
score, six general deficits were measured: (a) hair conditions (0–2); (b) position of ears (0–2); (c) eye
conditions (0–4); (d) posture (0–4); (e) spontaneous activity (0–4), and; (f) epileptic behavior (0–12).
For each of the six general parameters measured, animals received a score that correlated directly with
the degree of symptom severity, as previously reported [38,39]. The scores of investigated items were
then summed to provide a total general score ranging from 0 to 28. For the focal score, seven areas
were assessed: (a) body symmetry; (b) gait; (c) climbing; (d) circling behavior; (e) front limb symmetry;
(f) compulsory circling; and (g) whisker response. The severity of each of these items was rated on a
scale from 0 to 4. The seven items were then summed to give a total focal score ranging between 0 and
28. The single item does not provide any significant information per se. A higher score correlated with
the worst animal condition [38,39]. Ischemic volume, neurologic function, and animal survival were
evaluated in a blinded manner.
4.8. Experimental Protocol
Valproate and resveratrol were dissolved in saline and in dimethyl sulfoxide (DMSO) respectively
and administered intraperitoneally (i.p.) 30 min after the beginning of the reperfusion. The doses used
were 680 and 6800 µg/kg for resveratrol and 200 µg/kg and 20 mg/kg for valproate. Control mice
undergoing MCAO received vehicle solution in the same volume and on the same time schedule
as the valproate or resveratrol-treated animals. The doses used in vivo were chosen in the attempt
to obtain in the cerebrospinal fluid (CSF, 50 µL) pick concentrations that was effective on infarct in
our previous paper [9,56]. By considering that only 2% of plasmatic resveratrol can cross the blood
brain barrier (BBB) [56], to obtain a resveratrol concentration of 3 nmol/mL in the CSF, we injected
a dose of 68 µg/kg as starting dose. In present paper, we tested a dosage of 680 µg/kg in order to
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replicate the dosage scaling that led us to identify the resveratrol therapeutic dose of 6800 µg/kg.
We also approximated a total absorption through the i.p. route of administration and a compensation
of drug metabolism by increased BBB permeability after brain ischemia. Dosages of valproate were
chosen in order to predict an initial CSF concentration thirty times lower than that of resveratrol.
We also administered the drugs at 100-fold higher doses. Mice were sacrificed 24 h after the MCAO.
Body temperature, PaO2, PaCO2 and pH values were monitored for the entire experiment both
in control and drug-treated groups. Animals were randomly assigned either to the vehicle or the
compound treatment groups.
4.9. Statistical Analysis
Data obtained in cultured neurons were expressed as mean ± standard error and statistical
significance of differences between groups was evaluated by one-way ANOVA followed by Dunnet’s
multiple comparison test, using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA,
USA, version Prism 5). p < 0.05 was considered to be significant.
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